Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL14861666 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787913 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL12092460 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL26432 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL18497244 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL10550880 | 0.84 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL119382 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29431568 | 0.84 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL22476079 | 0.83 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL22616139 | 0.83 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | claimed |
| WO-2020016827-A1 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-01-23 | — | — | WO | claimed |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | disclosed |
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | disclosed |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2021-07-22 | — | — | US | disclosed |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2021-07-22 | — | — | US | disclosed |
| EP-3782989-A1 | DETOMIDINE HYDROCHLORIDE MONOHYDRATE | Sachse, Andreas (DE) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020016827-A4 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020016827-A1 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016827-A1 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016827-A1 | PURIFIED CRYSTALLINE DETOMIDINE HYDROCHLORIDE MONOHYDRATE, ANHYDRATE AND FREE BASE WITH LOW AMOUNTS OF ISO-DETOMIDINE AND OTHER IMPURITIES BY RECRYSTALLISATION IN WATER | CLEXIO BIOSCIENCES LTD. (IL) | 2020-01-23 | — | — | WO | disclosed |
| WO-2018087160-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR USE IN CONTROLLING PARASITIC CRUSTACEANS ON FISH | I-TECH AB (SE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | QDPR, DCTD, NEFM | ADRA2A 549/4885ADRA2B 634/4885ADRA2C 403/4885 |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | QDPR, DDT, DCTD | ADRA2A 316/4885ADRA2B 349/4885ADRA2C 165/4885 |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | QDPR, DDT, DCTD | ADRA2A 316/4885ADRA2B 349/4885ADRA2C 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.